Sandra M. E. Geurts

1.0k citations

59 papers · 612 indexed · h-index 14

Co-authors: Vivianne C. G. Tjan‐Heijnen Matthias A.W. Merkx André L. M. Verbeek Boukje A. C. van Dijk Jan L.N. Roodenburg Peter A. Brennan Irene E.G. van Hellemond Frans Erdkamp
Topics: Breast Cancer Treatment Studies (28 papers)Advanced Breast Cancer Therapies (15 papers)HER2/EGFR in Cancer Research (11 papers)
Cited by: Otorhinolaryngology Cancer Research Oncology
Journals: PLoS ONE Cancer Research Journal of Clinical Epidemiology
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Sandra M. E. Geurts

56 papers receiving 606 citations

Peers

Countries citing papers authored by Sandra M. E. Geurts

Since Specialization

Citations

This map shows the geographic impact of Sandra M. E. Geurts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra M. E. Geurts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra M. E. Geurts more than expected).

Fields of papers citing papers by Sandra M. E. Geurts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra M. E. Geurts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra M. E. Geurts. The network helps show where Sandra M. E. Geurts may publish in the future.

Co-authorship network of co-authors of Sandra M. E. Geurts

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra M. E. Geurts. A scholar is included among the top collaborators of Sandra M. E. Geurts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra M. E. Geurts. Sandra M. E. Geurts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients 2025 ·European Journal of Cancer ·(unknown),(unknown),Thiemo J. A. van Nijnatten,Sanne Engelen,Jolien Tol,Loes Kooreman,Marie-Jeanne T. F. D. Vrancken Peeters,Sabine Siesling,Adri C. Voogd,Vivianne C. G. Tjan‐Heijnen,Sandra M. E. Geurts	1
2	Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study 2025 ·The Breast ·(unknown),(unknown),Sandra M. E. Geurts,Jolien Tol,Birgit E. P. J. Vriens,(unknown),Eline Boon,M. Wouter Dercksen,Franchette van den Berkmortel,Manon J. Pepels,Natascha A. J. B. Peters,Joan B. Heijns,(unknown),(unknown),Vivianne C. G. Tjan‐Heijnen,Maaike de Boer	0
3	A review of the association between baseline [18F] fluorodeoxyglucose uptake and axillary pathological complete response in node-positive breast cancer patients: focus on clinical subtypes 2025 ·Nuclear Medicine Communications ·(unknown),(unknown),Felix M. Mottaghy,Sandra M. E. Geurts,Vivianne C. G. Tjan‐Heijnen,Marjolein L. Smidt,Thiemo J. A. van Nijnatten	1
4	202P Complete response rates, treatment patterns and survival outcomes in patients treated with first-line pertuzumab-based therapy in HER2-positive advanced breast cancer: A SONABRE study 2024 ·ESMO Open ·(unknown),Sandra M. E. Geurts,J. Tol,Birgit E. P. J. Vriens,(unknown),Eline Boon,M. W. Dercksen,F. Van den Berkmortel,Manon J. Pepels,Natascha A. J. B. Peters,Joan B. Heijns,(unknown),(unknown),V.C.G. Tjan-Heijnen,Maaike de Boer	1
5	The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry 2023 ·Breast Cancer Research and Treatment ·(unknown),(unknown),Ingeborg J. H. Vriens,(unknown),Sanne Engelen,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,(unknown),Manon J. Pepels,(unknown),Natascha A. J. B. Peters,Jolien Tol,Joan B. Heijns,Agnès J. van de Wouw,(unknown),Sandra M. E. Geurts,Vivianne C. G. Tjan‐Heijnen	4
6	Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry 2023 ·The Lancet Regional Health - Europe ·(unknown),Sandra M. E. Geurts,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,(unknown),Manon J. Pepels,(unknown),Natascha A. J. B. Peters,Jolien Tol,Joan B. Heijns,Agnès J. van de Wouw,(unknown),(unknown),Vivianne C. G. Tjan‐Heijnen	15
7	The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer 2023 ·JNCI Cancer Spectrum ·(unknown),Sandra M. E. Geurts,Irene E.G. van Hellemond,Astrid C P Swinkels,Carolien H. Smorenburg,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,W Roos,Sabine C. Linn,Alexander L.T. Imholz,Marjolein L. Smidt,Ingeborg J. H. Vriens,Vivianne C. G. Tjan‐Heijnen	4
8	Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial 2023 ·EClinicalMedicine ·Vivianne C. G. Tjan‐Heijnen,(unknown),Sandra M. E. Geurts,Ingeborg J. H. Vriens,Astrid C P Swinkels,Carolien H. Smorenburg,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,W Roos,Sabine C. Linn,Alexander L.T. Imholz	11
9	Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors 2023 ·Journal of Chemotherapy ·(unknown),(unknown),Sandra M. E. Geurts,(unknown),M. W. Dercksen,Vivianne C. G. Tjan‐Heijnen	1
10	Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry 2023 ·Clinical Breast Cancer ·(unknown),Sandra M. E. Geurts,(unknown),(unknown),Frans Erdkamp,Joan B. Heijns,Jolien Tol,Birgit E. P. J. Vriens,(unknown),M. Wouter Dercksen,Manon J. Pepels,Natascha A. J. B. Peters,(unknown),Agnès J. van de Wouw,(unknown),(unknown),Vivianne C. G. Tjan‐Heijnen	1
11	Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study 2022 ·European Journal of Cancer ·(unknown),(unknown),Jan Maarten van der Zwan,Stefan A.W. Bouwense,M. Wouter Dercksen,Ferry A.L.M. Eskens,Bastiaan Havekes,Johannes Hofland,Thomas Kerkhofs,Heinz‐Josef Klümpen,(unknown),Ernst‐Jan M. Speel,Frederik A. Verburg,Annemiek Walenkamp,Sandra M. E. Geurts,Judith de Vos‐Geelen	16
12	133O Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial 2022 ·Annals of Oncology ·V.C.G. Tjan-Heijnen,(unknown),Sandra M. E. Geurts,Ingeborg J. H. Vriens,Astrid C P Swinkels,Carolien H. Smorenburg,(unknown),Judith R. Kroep,H. de Graaf,(unknown),Frans Erdkamp,W Roos,Sabine C. Linn,Alex L.T. Imholz	3
13	Clinical value of contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: a population-based cohort study 2022 ·European Radiology ·(unknown),Sandra M. E. Geurts,Loes Kooreman,Luciën E. M. Duijm,Sanne Engelen,(unknown),Ernest J. T. Luiten,(unknown),Adri C. Voogd,Vivianne C. G. Tjan‐Heijnen	3
14	The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry 2021 ·International Journal of Cancer ·(unknown),Sandra M. E. Geurts,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,(unknown),Manon J. Pepels,(unknown),(unknown),Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	10
15	Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma 2021 ·International Journal of Cancer ·(unknown),Quisette P. Janssen,(unknown),Marc G. Besselink,Bert A. Bonsing,Stefan A.W. Bouwense,Sandra M. E. Geurts,Marjolein Y.V. Homs,Vincent E. de Meijer,Vivianne C. G. Tjan‐Heijnen,Hanneke W.M. van Laarhoven,Liselot Valkenburg‐van Iersel,Johanna W. Wilmink,Lydia G. van der Geest,Bas Groot Koerkamp,Judith de Vos‐Geelen,(unknown)	10
16	The Current Management of Ampullary Cancer: A Survey among Healthcare Workers Worldwide 2021 ·HPB ·E.M.G.J. de Jong,(unknown),Andrea Benedetti Cacciaguerra,Sandra M. E. Geurts,Liselot Valkenburg‐van Iersel,Hanneke Wilmink,Vivianne C. G. Tjan‐Heijnen,Marc G. Besselink,M.A. Hilal,(unknown)	0
17	Follow‐up after oral cancer treatment—Transition to a personalized approach 2020 ·Journal of Oral Pathology and Medicine ·(unknown),André L. M. Verbeek,Sandra M. E. Geurts,Matthias A.W. Merkx	4
18	Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry 2020 ·Quality of Life Research ·(unknown),Bram Ramaekers,D.J.A. Lobbezoo,Roel J.W. van Kampen,Maaike de Boer,Agnès J. van de Wouw,M. W. Dercksen,Sandra M. E. Geurts,Manuela Joore,Vivianne C. G. Tjan‐Heijnen	14
19	A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry. 2019 ·The Breast ·(unknown),Sandra M. E. Geurts,(unknown),Sander Croes,Birgit E. P. J. Vriens,Franchette W.P.J. van den Berkmortel,M. Wouter Dercksen,Agnès J. van de Wouw,Manon J. Pepels,(unknown),D.J.A. Lobbezoo,Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	1
20	Pattern of follow-up care and early relapse detection in breast cancer patients 2012 ·Breast Cancer Research and Treatment ·Sandra M. E. Geurts,Femmie de Vegt,Sabine Siesling,Karin Flobbe,Katja K.H. Aben,Margriet van der Heiden‐van der Loo,André L. M. Verbeek,J.A.A.M. van Dijck,Vivianne C. G. Tjan‐Heijnen	36

About Sandra M. E. Geurts

Sandra M. E. Geurts is a scholar working on Cancer Research, Otorhinolaryngology and Oncology, having authored 59 papers that have together received 612 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (28 papers), Advanced Breast Cancer Therapies (15 papers) and HER2/EGFR in Cancer Research (11 papers). The work is most often cited by research in Otorhinolaryngology (140 citations), Cancer Research (169 citations) and Oncology (293 citations). Sandra M. E. Geurts has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Vivianne C. G. Tjan‐Heijnen, Matthias A.W. Merkx, André L. M. Verbeek, Boukje A. C. van Dijk, Jan L.N. Roodenburg, Peter A. Brennan, Irene E.G. van Hellemond, Frans Erdkamp, J.A.A.M. van Dijck and Femmie de Vegt. Their work appears in journals such as PLoS ONE, Cancer Research and Journal of Clinical Epidemiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact